健民集團(600976.SH):一季度OTC渠道便通膠囊覆蓋率持續提升
格隆匯7月3日丨健民集團(600976.SH)接受特定對象調研時表示,便通膠囊是公司獨家產品,醫保乙類藥品,具有健脾益腎、潤腸通便的功效,可用於緩解脾腎不足、腸腑氣滯所致的便祕症狀。2023年OTC渠道銷售發出過億元,是OTC渠道第二個銷售過億的單品;2024年公司在全國範圍內進行廣吿投放,加大終端考核及精細化管理力度,一季度OTC渠道便通膠囊覆蓋率持續提升,銷售發出較上年同期增長約120%,因公司廣吿投入的增加,OTC渠道便通膠囊產生的銷售利潤暫無法完全覆蓋費用增長。我們對便通膠囊未來的發展充滿信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.